1
|
Gáll Z, Kelemen K, Mihály I, Salamon P, Miklóssy I, Zsigmond B, Kolcsár M. Role of Lacosamide in Preventing Pentylenetetrazole Kindling-Induced Alterations in the Expression of the Gamma-2 Subunit of the GABAA Receptor in Rats. Curr Mol Pharmacol 2020; 13:251-260. [DOI: 10.2174/1874467213666200102095023] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Revised: 11/24/2019] [Accepted: 12/03/2019] [Indexed: 12/20/2022]
Abstract
Background:
Epilepsy remains challenging to treat still no etiologic treatment has been identified,
however, some antiepileptic drugs (AEDs) are able to modify the pathogenesis of the disease.
Lacosamide (LCM) has been shown to possess complex anticonvulsant and neuroprotective actions,
being an enhancer of the slow inactivation of voltage-gated sodium channels, and it has the potential to
prevent epileptogenesis. Recent evidence has shown that LCM indirectly improves the function of
GABAA receptors. Receptors at most GABAergic synapses involve the gamma-2 subunit, which contributes
to both phasic and tonic inhibition, and its presence assures benzodiazepine sensitivity. Moreover,
mutant gamma-2 subunits were associated with generalized epilepsy syndromes. In animal models,
the expression of the gamma-2 subunit of the gamma-aminobutyric acid A receptor (GABAAg2) was
shown to be increased in pentylenetetrazole (PTZ)-induced chemical kindling in Wistar rats.
Objective:
This study hypothesized that LCM might affect the kindling process by influencing the
expression of GABAA receptors in the hippocampus.
Methods:
The gene and protein expression levels of the GABAAg2 were studied using RT-qPCR and
immunofluorescent staining.
Results:
It was found that LCM treatment (10 mg/kg i.p. daily for 57 days) reduced the maximal
intensity of the PTZ-induced seizures but did not prevent kindling. On the other hand, LCM treatment
reverted the increase of mRNA expression of GABAAg2 in the hippocampus and prevented the
decrease of GABAAg2 protein in the hippocampal CA1 region.
Conclusion:
LCM could exhibit modulatory effects on the GABAergic system of the hippocampus that
may be independent of the anticonvulsant action.
Collapse
Affiliation(s)
- Zsolt Gáll
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania
| | - Krisztina Kelemen
- Department of Physiology, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, Romania
| | - István Mihály
- Department of Physiology, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania
| | - Pál Salamon
- Department of Bioengeneering, Sapientia Hungarian University of Transylvania, Miercurea Ciuc, Romania
| | - Ildikó Miklóssy
- Department of Bioengeneering, Sapientia Hungarian University of Transylvania, Miercurea Ciuc, Romania
| | - Brigitta Zsigmond
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania
| | - Melinda Kolcsár
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania
| |
Collapse
|